Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | active not recruiting | Phase 3 | 160 | PharmaEssentiaINDUSTRY | 9 | Aug 13, 2026 | clinicaltrials |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance(SURPASS ET) | active not recruiting | Phase 3 | 174 | PharmaEssentiaINDUSTRY | 8 | Jul 22, 2026 |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE) | active not recruiting | Phase 3 | 313 | CelgeneINDUSTRY | 26 | Jul 16, 2026 | clinicaltrials |
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | active not recruiting | Phase 3 | 327 | Geron CorporationINDUSTRY | 26 | Jul 8, 2026 | clinicaltrials |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis(SENTRY) | active not recruiting | Phase 3 | 353 | Karyopharm Therapeutics IncINDUSTRY | 20 | Apr 9, 2026 | clinicaltrials |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis(TRANSFORM-2) | active not recruiting | Phase 3 | 330 | AbbVieINDUSTRY | 30 | Jan 9, 2026 | clinicaltrials |
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | active not recruiting | Phase 3 | 111 | PharmaEssentiaINDUSTRY | 2 | Aug 13, 2025 | clinicaltrials |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera(VERIFY) | active not recruiting | Phase 3 | 293 | Protagonist Therapeutics, Inc.INDUSTRY | 20 | Aug 7, 2025 | clinicaltrials |
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera(THRIVE) | active not recruiting | Phase 3 | 46 | Protagonist Therapeutics, Inc.INDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials